<DOC>
	<DOCNO>NCT00088075</DOCNO>
	<brief_summary>A clinical study evaluate efficacy , safety tolerability two dose range risperidone ( 1 3 mg/day , 4 6 mg/day ) versus placebo ( inactive substance like sugar pill ) adolescent ( age 13 17 year ) schizophrenia ( i.e . abnormal behavior thought ) . The study duration 6 7 week .</brief_summary>
	<brief_title>Investigate Risperidone Treatment Schizophrenia Adolescents</brief_title>
	<detailed_description>Subjects age 13 17 year diagnosis schizophrenia . On enrollment , subject assign receive 1 3 treatment ( oral placebo tablet , oral risperidone tablets 1 3 mg , oral risperidone tablets 4 6 mg ) , administer daily 6 week . Study medication increase within target dosage range first 7 day increase maximum tolerated dose achieve day 14 . The maximum tolerate dose maintain last 4 week study , unless dose adjustment agree Sponsor . Risperidone ( 1 3 mg 4 6 mg ) placebo give orally 0.5 , 1 , 2 , 3 , 4 , g tablet ( match placebo ) day 6 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>A responsible person must available accompany subject site visit patient must meet DSMIV criterion schizophrenia Patients mild , moderate severe mental retardation patient know suspected history substance dependence subject weigh &lt; 35kg subject swallow oral tablet</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Adolescents</keyword>
</DOC>